Larvol Delta - FDA-Grants-Arch-Biopartners-Permission-to-Proceed-with-Phase-II-trial-to-Evaluate-Metablok-LSALT-peptide-for-the-Treatment-of-COVID19-patients

MetaBlok (lsalt peptide) - Arch Biopartners

https://www.globenewswire.com/news-release/2020/06/16/2048962/0/en/FDA-Grants-Arch-Biopartners-Permission-to-Proceed-with-Phase-II-trial-to-Evaluate-Metablok-LSALT-peptide-for-the-Treatment-of-COVID-19-patients.html

Jun 16, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next